Overin Germ Hücreli ve Seks Kord-Stromal Tümörleri
Özet
Over kanseri kadınlarda sık görülen kanser türlerindendir. En sık görülen alt tipi epitelyal kaynaklı tümörler olmakla beraber, germ hücreleri ve seks kord-stromal hücrelerden de kaynaklanan çeşitleri vardır. Non-epitelyal kökenli bu kanser türleri daha genç yaşlarda görülmektedir. Genellikle genç yaşta ve erken evrede tespit edilen bu hastalıklarda tekrarlama riski nedeniyle uzun süreçli takip önerilir. Bu genç üreme çağındaki popülasyonunun mümkün olanlarında fertilite koruyucu cerrahi yapılması önerilmektedir ve bu durumda da takip sürelerinin daha uzun olması önerilmektedir. Tedavi ve takip için en önemli belirteç evredir. Serum tümör markerleri histolojik alt tip ve başlangıçtaki yükseklik durumuna göre takipte önemli yer oynar. Germ hücreli tümörlerde takip için önerilen görüntüleme yöntemi, ilk beş yıl giderek azalan sıklıkla, bilgisayarlı tomografi iken, seks kord-stromal tümörlerde rutin görüntüleme önerilmemektedir.
Ovarian cancer is one of the most common types of cancer in women. The most common subtype is epithelial tumors, but there are also varieties originating from germ cells and sex cord stromal cells. These non-epithelial cancer types are seen at younger ages. Long-term follow-up is recommended due to the risk of recurrence in these diseases, which are usually detected at a young age and at an early stage. Fertility-sparing surgery is recommended in this young reproductive age population, where possible, and in this case, longer follow-up periods are recommended. The most important marker for treatment and follow-up is stage. Serum tumor markers play an important role in follow-up according to histological subtype and initial elevation. The recommended imaging modality for follow-up in germ cell tumors is computed tomography, with decreasing frequency in the first five years, whereas routine imaging is not recommended in sex cord stromal tumors.
Referanslar
Mph RLS, Dvm AJ. Cancer statistics , 2024. 2024;(October 2023):12-49. doi:10.3322/caac.21820
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer : a review Pathologic classification of OC. Published online 2017:9-32. doi:10.20892/j.issn.2095-3941.2016.0084
Chen VW, Ph D, Ruiz B, Ph D, Killeen JL, Cote TR. Pathology and Classification of Ovarian Tumors. doi:10.1002/cncr.11345
Mehra P, Aditi S, Prasad KM, Bariar NK. Histomorphological Analysis of Ovarian Neoplasms According to the 2020 WHO Classification of Ovarian Tumors : A Distribution Pattern in a Tertiary Care Center. 2023;15(4):1-10. doi:10.7759/cureus.38273
Koulouris CR, Penson RT. Ovarian Stromal and Germ Cell Tumors. Semin Oncol. 2009;36(2):126-136. doi:10.1053/j.seminoncol.2008.12.004
Stettner AR, Hartenbach EM, Schink JC, et al. Familial ovarian germ cell cancer: Report and review. Am J Med Genet. 1999;84(1):43-46. doi:10.1002/(SICI)1096-8628(19990507)84:1<43::AID-AJMG9>3.0.CO;2-2
Gershenson DM. Management of ovarian germ cell tumors. Journal of Clinical Oncology. 2007;25(20):2938-2943. doi:10.1200/JCO.2007.10.8738
2024, UpToDate, Inc. Grafik 55817 sürüm 13. 0. No Title. https://www.uptodate.com/contents/treatment-of-malignant-germ-cell-tumors-of-the-ovary?source=history_widget
Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—An analysis of 376 women. Gynecol Oncol. 2007;104(2):396-400. doi:10.1016/j.ygyno.2006.08.032
Schultz KAP, Harris AK, Schneider DT, et al. Ovarian Sex Cord-Stromal Tumors. 2016;12(10). doi:10.1200/JOP.2016.016261
Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology and Obstetrics. 2021;155(S1):61-85. doi:10.1002/ijgo.13878
Mangili G, Sigismondi C, Lorusso D, et al. The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): The MITO-9 study. Annals of Oncology. 2017;28(2):333-338. doi:10.1093/annonc/mdw563
Ray-Coquard I, Morice P, Lorusso D, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2018;29:iv1-iv18. doi:10.1093/annonc/mdy001
Jerzak KJ, MacKay HJ. Ovarian sex cord-stromal tumors: The challenge of rare gynecologic malignancies. J Oncol Pract. 2016;12(10):947-948. doi:10.1200/JOP.2016.016998
Salani R, Backes FJ, Fung Kee Fung M, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466-478. doi:10.1016/j.ajog.2011.03.008
Ray-Coquard I, Brown J, Harter P, et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors. International Journal of Gynecologic Cancer. 2014;24(Supp 3):S42-S47. doi:10.1097/IGC.0000000000000249
Sun D, Zhi ZF, Fan JT. Could fertility-sparing surgery be considered for stage I ovarian sex cord-stromal tumors? A comparison of the Fine-Gray model with Cox model. Front Oncol. 2022;12. doi:10.3389/fonc.2022.964181
Liu J, Berchuck A, Backes FJ, et al. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network. 2024;22(8):512-519. doi:10.6004/jnccn.2024.0052
Al Harbi R, McNeish IA, El-Bahrawy M. Ovarian sex cord-stromal tumors: An update on clinical features, molecular changes, and management. International Journal of Gynecological Cancer. 2021;31(2):161-168. doi:10.1136/ijgc-2020-002018
D’Angelo E, Mozos A, Nakayama D, et al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Modern Pathology. 2011;24(10):1360-1367. doi:10.1038/modpathol.2011.95
Alexiadis M, Rowley SM, Chu S, et al. Mutational landscape of ovarian adult granulosa cell tumors from whole exome and targeted TERT promoter sequencing. Molecular Cancer Research. 2019;17(1):177-185. doi:10.1158/1541-7786.MCR-18-0359
Wang WC, Lai YC. Molecular pathogenesis in granulosa cell tumor is not only due to somatic FOXL2 mutation. J Ovarian Res. 2014;7(1). doi:10.1186/s13048-014-0088-0
Kalfa N, Ecochard A, Patte C, et al. Activating Mutations of the Stimulatory G Protein in Juvenile Ovarian Granulosa Cell Tumors: A New Prognostic Factor? J Clin Endocrinol Metab. 2006;91(5):1842-1847. doi:10.1210/jc.2005-2710
Young RH, Scully RE. Ovarian Sertoli - Leydig cell tumors. Am J Surg Pathol. 1985;9(8):543-569. doi:10.1097/00000478-198508000-00001
Taylor EC, Irshaid L, Mathur M. Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation. RadioGraphics. 2021;41(1):289-315. doi:10.1148/rg.2021200086
